Introduction
The major challenge in treating cancer is that many tumor cells carry mutations in key apoptotic genes such as p53, Bcl family proteins or those affecting caspase signaling, thus making treatment with traditional chemotherapeutic agents ineffective (Hollstein et al., 1994; McCurrach et al., 1997; Kondo et al., 2000; Devarajan et al., 2002; reviewed in Lowe, 1995; Soengas and Lowe, 2003) . The triggering of caspase independent death pathways, therefore, has become an attractive alternative approach to eradicating tumor cells. In addition to its importance in the treatment of cancer, caspase-independent processes have also been demonstrated to play a prominent role in mediating cell death following injury or disease (reviewed in Yu et al., 2003) . In this context, the inhibition of such alternate death pathways may have therapeutic potential in the treatment of stroke and neurodegenerative diseases. In this review, we will examine caspase-independent death mechanisms focusing on the following questions: What are the molecular mediators of caspase independent death? What is the mechanism by which these effectors are released from the mitochondria? Does this process require or involve caspases? A review of these studies will bring to light important regulatory targets controlling caspase-independent cell death as well as reveal ongoing controversies that require further study.
What are the caspase-independent death effectors?
The mitochondria are central relaying stations for both caspase-dependent and caspase-independent death pathways (reviewed in Tsujimoto, 2003) . Mitochondria respond to multiple death stimuli including those in which proapoptotic Bcl2 family proteins such as Bax/ Bak induce mitochondrial membrane permeabilization and cause the release of apoptotic molecules (reviewed in Gross et al., 1999; Newmeyer and Ferguson-Miller, 2003) (Goping et al., 1998; Gross et al., 1998; Ruffolo et al., 2000) . These proapoptotic molecules can also be released from the mitochondria independent of Bax/Bak by cellular perturbations that cause a sudden increase in intracellular calcium levels as seen following acute injuries such as myocardial infarction or stroke (reviewed in Weiss et al., 2003; Yu et al., 2003) . Thus, multiple death stimuli with or without the involvement of the classical Bcl family proteins converge on the mitochondria to trigger the release of proapoptotic molecules to initiate the death cascade ( Figure 1 ). Zou et al., 1997; Hu et al., 1999) . One of the key events in this pathway is the caspase-3-mediated cleavage of inhibitor of caspase-activated DNase (ICAD), which allows caspase-activated DNase (CAD) to enter the nucleus and cause oligonucleosomal DNA fragmentation Sakahira et al., 1998) . More recently, it has been demonstrated that permeabilized mitochondria can also release other proapoptotic factors such as Smac/Diablo and HtrA2/Omi (Du et al., 2000; Verhagen et al., 2000; Suzuki et al., 2001 ). Both of these proteins have been shown to facilitate caspase activation through their ability to bind to and inhibit the function of members of the IAP protein family (Liu et al., 2000; Martins et al., 2002) . Interestingly, HtrA2/Omi also possesses a serine protease activity, which has been shown to contribute to caspase-independent cell death processes (Suzuki et al., 2001) .
It has now been recognized that mitochondria can also release factors involved in caspase-independent cell death including apoptosis-inducing factor (AIF) and Endonuclease G (EndoG) (Susin et al., 1999b; Li et al., 2001; van Loo et al., 2001) . In fact, AIF is believed to play a central role in the regulation of caspaseindependent cell death Joza et al., 2001; Cregan et al., 2002; Yu et al., 2002) . This mitochondrial flavoprotein was first identified and characterized in the laboratory of Dr Guido Kroemer while examining apoptotic processes in cell free systems. In these experiments, supernatants derived from mitochondria, in which permeability transition had been induced, were shown to be capable of triggering chromatin condensation in isolated HeLa nuclei (Susin et al., 1996) . The soluble factor responsible for this activity was then identified as a mitochondrial protein that translocated to the nucleus following an apoptotic stimulus to induce chromatin condensation in a caspase-independent manner (Susin et al., 1999b) . The discovery of this soluble factor, which was AIF, opened the door to a new death pathway that could execute apoptosis-like cell death in the absence of caspase. Nascent AIF has a mitochondrial localization sequence that is cleaved upon entry into the intermembrane space (Susin et al., 1999b) . In healthy cells, AIF is retained in the mitochondria where it is believed to perform an oxidoreductase function based on the presence of a FAD binding domain in the N-terminal and its redox activity (Miramar et al., 2001) . The importance of this oxidoreductase role in normal cellular physiology derives from recent studies with the Harlequein (HQ) mice, which exhibit an 80% decrease in AIF levels due to a proviral insertion into the AIF gene (Klein et al., 2002) . AIF hypomorphic mice survive but exhibit a reduced tolerance to oxidative stress. Brain tissue obtained from these mice revealed oxidative stress and cerebellar degeneration after 7 months of age. These studies support the hypothesis that AIF has an important physiological function that includes regulation of oxidative processes. However, similar to the bifunctional role of cytochrome c, when AIF is released from the mitochondria in response to apoptotic stimuli it becomes an active executioner of the cell (Figure 2 ). Consistent with this bifunctional role, it has been shown that the FAD-binding domain of AIF is dispensable for its apoptotic activity (Loeffler et al., 2001; Miramar et al., 2001) and, in fact, the Caenorhabditis elegans ortholog of AIF (WAH1) lacks this FAD-binding function all together . Following nuclear translocation, AIF is believed to induce cell death at least in part, by triggering chromatin condensation. In cell free systems, incubation of isolated HeLa nuclei with recombinant AIF resulted in peripheral chromatin condensation and DNA loss associated with high molecular weight (50 kb), but not oligonucleosomal, DNA fragmentation (Susin et al., 1999b) . Further studies demonstrated that AIF could induce nuclear apoptosis in a variety of cell types when introduced by transient transfection, recombinant adenoviral infection or microinjection of rAIF (Susin et al., 1999b; Joza et al., 2001; Loeffler et al., 2001; Cregan et al., 2002; Yu et al., 2002) . These nuclear morpholo- Figure 1 Release of caspase-dependent and caspase-independent proapoptic factors from the mitochondria (in response to diverse signals) Figure 2 Multiple functions of AIF Caspase-independent cell death pathways SP Cregan et al gical and biochemical changes are consistent with those described in many caspase-independent death paradigms (reviewed in Leist and Jaattela, 2001) . Importantly, in the above studies it was shown that these effects of AIF were not inhibited by pharmacological caspase inhibitors such as zVAD or BAF, indicating that AIF can trigger nuclear apoptosis in a caspaseindependent manner. The importance of AIF nuclear translocation in the execution of cell death has been demonstrated in several systems by microinjection of neutralizing antibodies against AIF. Specifically, inhibition of AIF translocation was shown to inhibit nuclear apoptosis in fibroblasts exposed to staurosporine, atractyloside (Susin et al., 1999b) or the alkylating agent MNNG . Similarly, neutralization of AIF protected neurons against DNA damage (Cregan et al., 2002) or pneumococcus-induced apoptosis (Braun et al., 2001) . Furthermore, targeted disruption of the AIF gene was shown to inhibit the first wave of programmed cell death that occurs during embryogenesis (Joza et al., 2001) . During the process of cavitation of embryoid bodies (EB), cells within the inner core are eliminated by apoptosis. Although this death process is normally associated with caspase-3 activation, it was demonstrated that AIF translocation and cell death could still proceed in the presence of the caspase inhibitor zVAD or in Apaf-1-or caspase-9-deficient cells (Joza et al., 2001) . In contrast, programmed cell death and cavitation did not occur in AIF-deficient EB. In addition to these studies, the nuclear translocation of AIF during apoptosis has been demonstrated in response to numerous stimuli and in diverse cell types (reviewed in Granville et al., 2001a; Braun et al., 2002; Fonfria et al., 2002; Zhang et al., 2002; Cao et al., 2003; Jambrina et al., 2003; Kim et al., 2003; Murahashi et al., 2003; Zhu et al., 2003) .
Once mitochondrial factors are released how do they participate in the apoptotic cascade?
One of the main functions of AIF is to translocate to the nucleus and initiate large-scale (50 kb) DNA fragmentation. Examination of the AIF crystal structure together with structure function analysis has demonstrated that AIF can bind DNA in a sequence-independent manner . The importance of this DNA-binding domain was demonstrated by the use of site-directed AIF mutants. While retaining nuclear translocation capability, AIF-DNA-binding mutants failed to induce cell death (Ye et al., 2002) . However, in vitro studies using recombinant AIF or its C. elegans homolog, WAH-1, have indicated that AIF itself cannot cleave DNA (Susin et al., 1999b; Wang et al., 2002) . Thus, it is believed that upon entry into the nucleus, AIF recruits or activates an endonuclease to facilitate DNA fragmentation and chromatin condensation (Ye et al., 2002) . While little is known regarding AIF-interacting targets in mammalian cells, recent work in C. elegans has begun to shed light on its possible mechanism of action ( Figure 3) . Inactivation of WAH1, an AIF homolog, was shown to impair DNA degradation and delay apoptosis during development . It was further shown that WAH1 associates with CPS-6, the C. elegans homolog for the mammalian endonuclease, EndoG, to promote apoptotic DNA degradation. In vitro studies demonstrated that while CPS6 (EndoG) possesses low nuclease activity on its own, coincubation with WAH-1 greatly enhanced its activity . In further studies it was shown that WAH1 and CPS6 participated in a nuclear complex referred to as the 'degradasome' involving downstream nucleases such as CRN1 and other unknown factors (Parrish et al., 2003) .
In mammalian cells, it has been reported that EndonucleaseG, like AIF, translocates from the mitochondrial to the nucleus during apoptosis and is capable of inducing DNA fragmentation independent of caspases . In cell free systems, recombinant EndoG could induce DNA fragmentation in isolated nuclei and was capable of cleaving plasmid DNA. Two separate studies have shown that BH3 only proteins, such as tBid and Bim, could induce the release of EndoG from isolated mitochondria and this process could be inhibited by Bcl2 van Loo et al., 2001) . In these studies, EndoG-mediated DNA fragmentation was not affected by zVAD, suggesting that this endonuclease functions in a caspase-independent manner. EndoG was also found to induce DNA fragmentation in cells derived from mice deficient for DFF45/CAD, which lack the key caspase-dependent DNA fragmentation factor . Taken together, these data suggest that EndoG does not require caspase to initiate DNA degradation pathways. This finding is in contrast to another study in which it was shown that tBid itself is not sufficient to mediate mitochondrial EndoG release from isolated mitochondria since EndoG was found to be tightly bound to the inner mitochondrial membrane or localized in the matrix (Arnoult et al., 2003) . While recent studies with Figure 3 The BH3-like protein Egl-1 initiates WAH-1 nuclear translocation in a caspase (CED-3)-dependent manner in C. elegans C. elegans have shown an interaction between WAH1 and CPS6 whereby WAH1 activates CPS6 endonuclease activity , no such interaction has yet been reported in mammalian cells and little is known regarding AIF interacting proteins. In fact, studies examining AIF-or EndoG-mediated DNA fragmentation have suggested that in nuclei from mammalian cells, these factors can induce nuclear chromatin breakdown independent of one another (Susin et al., 1999b; Li et al., 2001) . Similar to C. elegans, mammalian cells likely involve a more complex repertoire of endonucleases that interact with AIF to facilitate degradation of chromatin. Thus, the interacting factors of EndoG and AIF as well as the components that comprise the degradeosome in mammalian cells have yet to be identified.
AIF participates in multiple death paradigms
It is important to realize that higher mammals have evolved complex death pathways, many of which feed into apoptotic programs that converge on the mitochondria as a key regulatory component (Park et al., 1998) . In general, there are two types of cell death that should be considered: First, there are death pathways that occur in many different cell types in which Bcl/Bax and caspases are not required ( Figure 4 ). Here, death is often triggered by excessive calcium influx that results in poly(ADP-ribose) polymerase (PARP) overactivation (Yu et al., 2003) . Second, there are death pathways that traditionally involve Bcl family proteins and caspases ( Figure 5 ). Such pathways may recruit an additional response mechanism such as caspase-independent AIF release to facilitate the completion of apoptosis. These distinct apoptotic paradigms will be discussed below.
AIF in Bcl/Bax-independent pathways
The first death paradigm does not directly involve the bcl family or caspase as central regulators. Instead, mitochondria are triggered to release their proapoptotic molecules by a distinct mechanism that does not require caspase activation (reviewed in Yu et al., 2003) . A key molecule in this type of cell death is poly(ADP-ribose) polymerase-1 (PARP1), which mediates the release of AIF . This type of cell death is seen in a number of injury models involving many different cell types, including pancreatic islets, cardiac myocytes and neuronal cells (Pieper et al., 1999a (Pieper et al., , b, 2000 . More recently, similar caspase-independent AIF release mechanisms have also been described in tumor tissue and cultured cells (Joseph et al., 2002; Alonso et al., 2003; Liao and Dickson, 2003) . In these experiments, tumor cells exhibited nonclassical features of apoptosis, showing no caspase activation, intact PARP1 and AIF nuclear translocation. These findings suggest that in tumor tissue, PARP1 may also function in the absence of caspase to facilitate AIF release and nuclear translocation. The importance of PARP1 activity in caspase-independent cell death is underscored by the profound protection observed when PARP1 activity is inhibited or the gene has been deleted by homologous recombination. For example, PARP1-null mice are resistant to streptozotocin-induced pancreatic islet destruction or damage induced by reactive oxygen species (Heller et al., 1995; Burkart et al., 1999; Masutani et al., 1999; Pieper et al., 1999a, b) . In other injury models such as myocardial infarction, the absence of PARP1 activity either by the use of pharmacological blockers or with knockout mice provides significant protection from cell death (Bowes et al., 1998; Pieper et al., 2000) . In these studies, the absence of PARP1 resulted in enhanced survival of cardiac myocytes and reduced infarct volume. PARP1-deficient mice also exhibit a remarkable resistance to cerebral ischemia (Eliasson et al., 1997; Goto et al., 2002) , which is a complex injury involving death signaling initiated by inflammation, hypoxia and excitotoxic injury. To best illustrate this caspase-independent mechanism, we will Figure 4 Mechanism of caspase-independent PARP-mediated release of AIF. Excitotoxic cell death is shown as a typical example, where death is initiated by calcium influx triggering PARP activation Figure 5 Mechanisms of Bax-mediated mitochondrial membrane permeabilization and AIF release. Traditional apoptotic cell death involving Bcl family protein and caspase activation. In this death cascade, AIF and Cyto C release can be triggered by different modes of Bax-mediated mitochondrial permeabilization discuss excitotoxic injury of the nervous system as a specific example. This type of injury plays a prominent role in cell loss caused by stroke, nervous system trauma as well as in neurodegenerative diseases such as Parkinson's disease (reviewed in Sattler and Tymianski, 2000; Betarbet et al., 2002) . Previous studies have shown that the absence of PARP1 affords a striking protection against excitotoxic insults (Eliasson et al., 1997; Mandir et al., 2000) .
Excitotoxic injury is due to the release of abnormally high amounts of the excitatory neurotransmitter, glutamate, from synapses (Schwarcz and Whetsell, 1982; Rothman and Olney, 1986) . This. coupled with impaired reuptake of glutamate following stroke or trauma. exacerbates the excitotoxic response through sustained activation of glutamate receptors (reviewed in Choi, 1988; Meyer, 1989) . This mode of injury also occurs as a result of nervous system trauma and in neurodegeneration such as in Parkinson's disease (reviewed in Betarbet et al., 2002) . While there are several receptors for excitatory amino acids, NMDA receptors are believed to be the key mediators of death in excitotoxic injury whereby glutamate overstimulation leads to excessive calcium influx and elevation of cytoplasmic calcium levels (reviewed in Sattler and Tymianski, 2000) . Calcium influx has been shown to activate second messengers, one of which is neuronal nitric oxide synthase (nNOS) (Castilho et al., 1998; Stout et al., 1998; Sasaki et al., 2000) . This leads to the generation of excessive levels of nitric oxide that serves as a substrate for the generation of highly reactive peroxynitrites (Beckman, 1991; Beckman and Crow, 1993) . In parallel, elevated cytoplasmic calcium levels also cause mitochondrial depolarization and impaired electron transport due to loss of membrane potential (Nicholls and Budd, 2000) . Failed oxidative phosphorylation also results in the generation of reactive oxygen species such as superoxide, which reacts with NO to generate peroxynitrites (Dalkara et al., 1998; Endres et al., 1998) . DNA damage induced by the resultant reactive oxygen species triggers multiple death pathways, one of which is PARP1 overactivation (Virag and Szabo, 2002) . While this is a protein that is involved in a number of biological functions, there is extensive evidence demonstrating that PARP1 plays a critical role in controlling caspase-independent death mechanisms ( Figure 4 ). PARP1, a nuclear enzyme activated by DNA damage, participates in DNA repair, the regulation of transcription, DNA replication, cell differentiation, proliferation and cell death (Lautier et al., 1993; de Murcia and Menissier de Murcia, 1994; Shall and de Murcia, 2000; Virag and Szabo, 2002) . PARP is not only involved in cell death in neuronal systems such as ischemia and MPTP toxicity (model for Parkinson's disease) but also in myocardial infarction, diabetes, inflammation and the death of tumor cells (Kukreja and Hess, 1992; Wang and Zweier, 1996; Burkart et al., 1999; Masutani et al., 1999) . Following excitotoxic injury, PARP becomes overactivated following DNA damage where it causes poly ADP-ribosylation of many nuclear proteins using NAD þ as substrate. After binding to DNA strand breaks, PARP activity increases 500-fold, leading to excessive consumption of cellular energy stores (Benjamin and Gill, 1980; Menissier-de Murcia et al., 1989; Lautier et al., 1993; Smulson et al., 2000) . Owing to the rapid energy depletion resulting from PARP overactivation, the death mechanism that results from this pathway has been considered necrotic. Indeed, the absence of PARP has been shown to be protective against a number of insults that present a necrotic-like cell death, including excitotoxicity, myocardial ischemia, inflammation by zymosan and streptosotocin-induced diabetes (reviewed in Yu et al., 2003) . The absence of PARP does not seem to affect the rate of cell death involving bcl/bax propagated pathways that yield a more classical apoptotic morphology as seen, for example, in neurons exposed to staurosporine, cholchicine or potassium withdrawal (Leist et al., 1997) . Of note is the fact that PARP is normally cleaved by caspases into characteristic 89 and 24 kDa fragments during apoptotic cell death (Kaufmann et al., 1993; Lazebnik et al., 1994) . PARP1 cleavage has likely evolved to preserve sufficient energy to facilitate the successful execution of caspase-mediated apoptosis.
Since studies with PARP1-null mice and pharmacological blockers have shown that PARP1 is a key regulator of death in a broad spectrum of cells and diseases, an important question is 'How does PARP overactivation induce cell death and what are the downstream targets?' A recent study by has identified AIF as a key mediator of PARPinduced caspase-independent cell death. Immortalized embryo fibroblasts isolated from PARP1-deficient and wild-type mice were treated with N-methyl-N 0 -nitro-Nnitrosoguanidine (MNNG) . This DNA alkylating agent is a potent activator of PARP1 and induces cell death within 12-24 h. The cells die by an apoptotic-like mechanism since there is an orderly sequence of events involving mitochondrial depolarization, the release of AIF and cytochrome c and chromatin condensation. In contrast to wild-type cells, PARP1-deficient cells failed to induce AIF translocation or cytochrome c release and exhibited complete protection from MNNG. AIF was essential for PARPmediated cell death since blocking AIF nuclear translocation with AIF neutralizing antibodies inhibited cell death. Similar results were obtained examining NMDAmediated excitotoxicity in neuronal cells. NMDA evokes a rapid PARP1 activation and subsequent AIF translocation that precedes neuronal death. NMDAinduced AIF translocation and cell death was blocked in neurons derived from PARP1-null mice or in wild-type neurons in the presence of the pharmacological PARP1 inhibitor DPQ . Both death models require PARP1 activation to cause AIF to translocate to the nucleus and initiate chromatin condensation. Clearly, these are caspase-independent death models since caspase inhibitors such as BAF or ZVADfmk have no affect on the rate of cell death or AIF translocation. Later events following AIF translocation include a release of cytochrome c and some detectable caspase activation . These events, however, occur during end stages of cell death and are not considered as key determinants of AIF release or the progress of cell death. Since PARP1 is a substrate for caspase cleavage, it appears that overactivation of PARP1 as a death stimulus is mechanistically distinct from caspase-mediated cell death. Caspase activation would quickly extinguish PARP1 activity, thereby preventing its overactivation. In caspase-mediated death mechanisms, the rapid cleavage of PARP1 would provide an energy conservation mechanism to facilitate classical apoptosis. Consistent with this, many wellknown caspase-mediated death mechanisms are refractory to PARP1 inhibition (Leist et al., 1997) . In summary, cell death involving PARP1 overactivation reveals a mechanism whereby mitochondrial AIF is released as a death-initiating pathway, which is distinct from the Bax/Bak, caspase-mediated release of AIF. A key question that remains to be addressed is 'how does PARP1 trigger the release of AIF?' Does PARP1 cause AIF release indirectly by the depletion of cellular NAD þ ? This would deplete not only cellular energy stores but also the cellular reducing capacity and thereby further sensitize the cells to oxidative damage. Alternatively, could PARP1 initiate a specific signal potentially by causing the ADP-ribosylation of a key regulatory protein? Recently, a study showed that inhibition of mitochondrial PARP1 prevented the release of AIF and cell death induced by peroxynitrite or glutamate exposure (Du et al., 2003) . This suggests that PARP1 may affect AIF release by acting directly in the mitochondria. Future studies will help to clarify this very interesting death pathway.
AIF in Bcl/Bax-mediated death pathways
In the second death paradigm, AIF participates in a death cascade that traditionally involves Bcl/Bax and caspases ( Figure 5) . A number of studies convincingly demonstrate that the release of AIF can be regulated by the Bcl protein family. For example, it has been shown that AIF translocation in response to p53 death signaling is abrogated in Bax-deficient neurons (Cregan et al., 2002) and transient overexpression of Bax was shown to trigger the release of AIF in 293T and HeLa cells (Arnoult et al., 2002; Arnoult et al., 2003) . Similarly, enforced expression of the BH3-like protein Egl-1 in C. elegans initiated wah-1 nuclear translocation . Finally, it has been shown in several death paradigms that overexpression of the antiapoptotic family member Bcl-2 prevents the release of AIF and consequent cell death (Susin et al., 1999b; Cregan et al., 2002) .
While there is a general consensus that AIF functions downstream of the bcl family, its function in relation to caspase activation remains a subject of considerable debate. In one model, it is suggested that AIF functions upstream and independent of caspase activation (Susin et al., 1999a, b; Daugas et al., 2000; Yu et al., 2002) . Alternatively, in a second model it has been proposed that AIF can function independent of caspases and may act as a secondary response to ensure the completion of apoptosis (Cregan et al., 2002) . Finally, in a third model it is suggested that AIF function is downstream and strictly dependent on caspase activation (Arnoult et al., 2002; Arnoult et al., 2003) . These different models are discussed below.
Studies from many laboratories examining numerous death paradigms have shown that AIF can translocate to the nucleus to execute chromatin condensation and apoptosis by a mechanism that does not require caspases (Susin et al., 1999b; Daugas et al., 2000; Joza et al., 2001; Loeffler et al., 2001; Cregan et al., 2002; Yu et al., 2002; Zhang et al., 2002) . Two particular studies, described below, have provided compelling evidence demonstrating that AIF is a caspase-independent death effector that can function in parallel and independent of the mitochondrial activated caspase cascade.
In the first study, cytosolic extracts obtained from MEFs undergoing apoptosis in response to staurosportin, etoposide or cisplatin were employed to induce chromatin condensation and DNA fragmentation in isolated HeLa nuclei . Immunodepletion of AIF and addition of ICAD abolished the nuclear apoptotic activity within these extracts. Either treatment alone, however, did not suffice to prevent nuclear apoptosis, although the addition of ICAD did prevent the appearance of advanced stages of chromatin condensation (stage II) and oligonucleosomal DNA fragmentation. Additional experiments demonstrated that extracts obtained from Apaf1 or caspase3-deficient MEFs were still capable of inducing stage I nuclear apoptosis (partial chromatin condensation), but that immunodepletion of AIF from these extracts neutralized this activity. In the second study, Cregan et al. (2002) demonstrated that during p53-induced cell death of postmitotic neurons, cytochrome c is released followed by mitochondrial membrane permeabilization and AIF translocation. This sequence of events resulted in classical apoptotic (stage II) nuclear morphology. However, in the presence of BAF or in Apaf1-deficient neurons, p53-induced cell death was delayed, but caspase inhibition did not prevent the eventual translocation of AIF and the appearance of stage I nuclear apoptotic morphology. Furthermore, microinjection of AIF neutralizing antisera prevented p53-induced nuclear apoptosis in Apaf1-deficient cells, but had no effect on wild-type cells. Taken together, these results suggest that AIF and caspases can function independent of one another to trigger apoptotic cell death. Thus, in addition to a primary role for AIF in some death pathways (Susin et al., 1999b; Joza et al., 2001; Yu et al., 2002) , it appears that in certain situations AIF may function to activate an alternative apoptotic mechanism when caspases are inactive (Cregan et al., 2002) .
Over the past 4 years, the literature has suggested that AIF can function in a caspase-independent manner; however, recently several reports have emerged from studies in C. elegans and mammalian cells challenging this contention. Studies with C. elegans have revealed that the AIF homolog, WAH1, was released from mitochondria in a caspase-dependent manner . This was clearly evident when Ced3 (caspase) mutants were examined for naturally occurring developmental apoptosis. In the absence of caspase (ced3) activity, WAH1 could not be efficiently released from the mitochondria. While there was a slight release of WAH1 in these mutants, it seems evident that naturally occurring cell death in C. elegans requires caspase (ced3) activity to mediate an AIF/WAH1 death response. Interestingly, in certain mammalian developmental programmed cell death models, AIF release occurred efficiently in the absence of caspase activation (Joza et al., 2001) . While studies with C. elegans reveal important insights into these death mechanisms, there are also significant differences from mammalian cells. One key example is that C. elegans does not release cytochrome c to activate caspase activity (Yang et al., 1997) . Thus, it is highly probable that WAH1/AIF function in C. elegans exemplifies a more primitive apoptotic mechanism, which has since evolved in mammalian cells. In higher animals, AIF may be released by alternative mechanisms in addition to the dependence on caspase.
Within the last year, additional reports involving mammalian cells have appeared, demonstrating that under certain conditions mitochondrial AIF cannot be released in the absence of caspase activity (Arnoult et al., 2002; Arnoult et al., 2003) . To determine whether caspase is required for AIF release, Hela cells were treated with the proapoptotic agents, staurosporine or actinomycin D, in the presence or absence of the caspase inhibitor, z-VADfmk. When caspases were inhibited, AIF failed to translocate from the mitochondria into the nucleus demonstrating that caspase activity may be required for AIF release. Further studies examining events downstream from Bax/Bak mitochondrial permeabilization revealed that caspase activation was required for mitochondrial release of AIF and EndoG. In these studies, cells treated with zVADfmk were able to release the mitochondrial proteins Cytochrome c, Smac/Diablo and HtrA2/Omi but not EndoG or AIF (Arnoult et al., 2003) . Taken together, these experiments convincingly demonstrate a caspase requirement for AIF release in this apoptotic model. Surprisingly, studies performed by other groups using similar systems have revealed that AIF could readily translocate from the mitochondria to the nucleus despite the absence of caspase (Susin et al., 1999a, b; Daugas et al., 2000; Susin et al., 2000; Yu et al., 2002) .
Understanding the role of caspase in AIF release
How does one rationalize these opposing views on the role of caspases in mediating the release of AIF from the mitochondria? In fact, several factors could account for this seemingly contradictory literature including cell type-and stimulus-specific responses (Figure 6 ). For example, in primary cortical neuron cultures it was shown that during DNA damage-induced cell death, AIF translocation followed the release of Cytochrome c (Cyt c), but in contrast to certain non-neuronal cells this was not dependent on caspase activation. One possible explanation is that in neurons, when Bax induces the release of cytochrome c and depolarizes the mitochondrial membrane, the ensuing energy crisis can trigger a secondary excitotoxic response. As previously mentioned, during excitotoxicty PARP1 activation can trigger the release of AIF independent of caspase activation Zhang et al., 2002) . Alternatively, the absence of caspase may allow PARP1 activation and thereby facilitate caspase-independent release of AIF. It remains to be determined whether PARP1 is responsible for this caspase-independent release of AIF; however, if it is involved it would likely be relevant only to conditions in which caspases are inhibited since PARP1 itself is a caspase target (Lazebnik et al., 1994) .
It is also possible that the necessity for caspases in mediating Bax-induced AIF release may be affected by other cofactors that contribute to mitochondrial membrane permeabilization. Indirect evidence for this comes from studies in Bax-dependent/caspase-mediated neuronal cell death paradigms (Park et al., 1998; Cregan et al., 1999; Johnson et al., 1999; Stefanis et al., 1999) . In sympathetic neurons, for example, apoptosis induced by nerve growth factor withdrawal is delayed by several days in the presence of caspase inhibitors (Deshmukh et al., 2000) . In contrast, under similar conditions cerebellar granule neurons, undergoing potassium/serum deprivation-induced cell death, show only a very transient protection and death ensues within a few hours (Miller et al., 1997) . In both cases, commitment to caspase-independent cell death appears to coincide with the onset of bax-mediated mitochondrial depolarization and this delayed cell death can be further attenuated in the presence of the PTP inhibitor cyclosporine-A (Chang and Johnson, 2002; Chang et al., 2003) . Therefore, the substantial difference in the delay of mitochondrial depolarization and cell death that occurs in the absence of caspases suggests that other cell type-specific factors must contribute to this process. Although the relative kinetics of AIF release has not been examined in these death paradigms, a recent report has indicated that caspase-independent AIF translocation does occur in potassium-deprived cerebellar granule neurons (Slagsvold et al., 2003) .
Another consideration to account for this discrepancy is the cell type-and stimulus-specific involvement of other cellular organelles. Recent reports have indicated that in addition to their affects on mitochondrial permeabilization, the Bcl protein family can also affect permeability and calcium signaling from the endoplasmic reticulum in a stimulus-specific manner (Lee et al., 1999; Granville et al., 2001b; Germain et al., 2002; Nutt et al., 2002; Scorrano et al., 2003) . Thus, it is possible that the mode and extent of mitochondrial permeabilization induced by Bcl proteins may be influenced by the level of calcium signaling coming from the endoplasmic reticulum. This is of particular interest since mitochondrial calcium loading is considered to be a critical process in the triggering of excitotoxic cell death, which can trigger caspase-independent AIF release (described above) (Gwag et al., 1995; Mattson et al., 2000) . Furthermore, it has recently been demonstrated that staurosporine can trigger the release of cathepsin D from lysozymes in human T -lymphocytes, which can function in combination with Bax to facilitate the release of AIF (Bidere et al., 2003) . To this end, the cathepsin D inhibitor pepstatinA was able to inhibit the release of AIF and early apoptotic events. These data suggest the possibility that other proteases may compensate for the absence of caspases in releasing AIF. Taken together, it becomes apparent that certain death paradigms require caspase to release AIF but many cell types have recruited alternative mechanisms that come into play to ensure the completion of apoptosis. This would be considered an advantage since the tissue would be spared from an inflammatory response due to necrotic cell death.
What are the mechanisms regulating the sequential order of release of proapoptotic molecules from the mitochondria?
Another question that arises when examining different death paradigms pertains to the sequential ordering of the release of mitochondrial proapoptotic factors. Based on a number of studies, there appears to be a precise sequence of mitochondrial events culminating in the demise of the cell. As with the requirement for caspase in AIF release, however, there is considerable controversy regarding the ordering of these key apoptotic events. In the following section, we will discuss the mechanisms involved in the release of proapoptotic factors and attempt to place AIF and EndoG in this context.
In traditional Bcl family/caspase-mediated death cascades, the mitochondrial release of proapoptotic factors is initiated by the activation of proapoptotic Bcl family proteins (reviewed in Cory and Adams, 2002) . The question as to how these proteins regulate the release of apoptogenic molecules from the mitochondria has not yet been resolved. However, several mechanisms have been proposed: first, studies in cell free systems using lipid vesicles have shown that proapoptotic family members such as Bax or Bak can homo-oligomerize to form a pore sufficient for the release of 70 kDa molecules (Antonsson et al., 2000; Saito et al., 2000; Basanez et al., 2001; Kuwana et al., 2002) . This model suggests that proapoptotic Bcl family members alone may be sufficient to cause pore formation in the outer mitochondrial membrane. While this has only been demonstrated using in vitro systems, large complexes containing Bak and Bax have been observed by electron microscopy on the mitochondrial outer membranes (Nechushtan et al., 2001) . These findings provide in vivo support for the hypothesis that Bcl2 family members alone are sufficient to form Cytochrome c conducting channels. Second, other studies suggest that proapoptotic family members can form complexes with mitochondrial membrane proteins such as the voltage-dependent anion channel (VDAC) to yield pores sufficient for the release of 100 kDa. Microinjection of VDAC antibodies directed against the entrance of the channel inhibited the release of mitochondrial cytochrome c and prevented apoptosis from occurring. These data suggest that Baxmediated cytochrome c release occurs through VDAC (Narita et al., 1998; Shimizu et al., 1999; Shimizu et al., 2001) . More recently, mitochondrial permeabilization is thought to also occur by fission, whereby Bax associates with the protein Drp1 to facilitate mitochondrial fragmentation (Karbowski et al., 2002) . Mitochondrial fission is thought to be responsible for the release of a number of factors including cytochrome c (Frank et al., 2001) . Finally, a mechanism that likely occurs in most cells at the end stages of apoptosis is the rupture of the outer mitochondrial membrane (Vander Heiden et al., 1997) . The loss of the mitochondrial membrane potential is thought to cause swelling of the matrix (Crompton, 1999; Parone et al., 2002) . This swelling of the inner membrane causes a distortion of the cristae structure, rupture of the outer mitochondrial membrane and release of additional mitochondrial-associated proteins. This model would suggest a nonspecific release of proapoptotic proteins residing in the intermembrane space. In fact, some studies examining cytochrome c release propose that mitochondrial permeabilization is a two-step process, whereby pore formation of the outer membrane leads to the release of small amounts (o15%) of cytochrome c (Ott et al., 2002; Scorrano et al., 2002) . At this early stage of mitochondrial permeabilization, the process is thought to be reversible since previous studies have shown that mitochondria can undergo a reuptake of Cytochrome c and thereby arrest the death process (Martinou et al., 1999; Fletcher et al., 2000) . If apoptosis continues, however, the loss of mitochondrial membrane potential may lead to the rupture of the outer membrane or the opening of specific channels responsible for the release of the greater portion of cytochrome c in addition to other apoptogenic molecules. The relevance of each of these models likely depends on the cell type and the death stimulus involved.
Studies examining the relative kinetics of AIF and cytochrome c release have yielded apparently conflicting views. On the one hand, it has been demonstrated that at early times following exposure to staurosporine, a significant population of cells (36%) exhibit nuclear AIF translocation and partial chromatin condensation (stage I nuclear apoptosis) without detectable levels of cytosolic cytochrome c . At later times, however, the majority of cells exhibit release of both AIF and cytochrome c and exhibit advanced (stage II) nuclear chromatin condensation. While these data suggest that AIF translocation can precede cytochrome c release, it remains possible that these immunofluorescence studies were not sufficiently sensitive to detect the earlier release of a subpool of cytochrome c. This would be consistent with the twostep model of cytochrome c release that has recently been demonstrated (Ott et al., 2002; Scorrano et al., 2002) . The early release of AIF has also been demonstrated in fibroblasts treated with the DNA-alkylating agent MNNG . Here, it was shown that translocation of AIF and nuclear chromatin condensation could occur within 15 min of MNNG exposure. In contrast, cytochrome c dissipation and caspase activation was not evident until approximately 1-2 h after treatment. It is important to note, however, that in this death paradigm AIF release and cell death are regulated by PARP-1 signaling and not via the actions of the Bcl protein family .
In other studies in which AIF release has been shown to be regulated by Bax-mediated mitochondrial permeabilization, it has been demonstrated that cytochrome c release can precede AIF translocation. This has been demonstrated in cortical neurons following exposure to the genotoxic agent camptothecin (Cregan et al., 2002) as well as in HeLa cells following overexpression of Bax or treatment with staurosporine or actinomycinD (Arnoult et al., 2002) . In the latter case, the relative kinetics was inferred by the fact that AIF release did not occur in the absence of cytochrome c-dependent caspase activation.
In almost all death paradigms examined, the release of AIF appears to coincide with the loss of mitochondrial membrane potential (Susin et al., 1999b; Ferri et al., 2000; Cregan et al., 2002) . However, mitochondrial depolarization alone may not be sufficient to trigger the release of AIF, suggesting that other factors must contribute to this process (Arnoult et al., 2003) . Thus, it is likely that depending on the death stimulus other cellular factors can affect the mode and extent of mitochondrial permeabilization and thereby alter the rate of AIF and cytochrome c release. Perhaps, under conditions in which Bax acts autonomously to form pores, only the outer mitochondrial membrane becomes permeabilized and only cytochrome c is released. However, if Bax engages the PTP directly or if permeabilization is associated with significant calcium influx, then AIF can be released more rapidly. An interesting point of contention is whether AIF exists as a soluble intermembrane factor or is bound to the inner mitochondrial membrane. Mitochondrial subfractionation studies have yielded opposing views on this point (Susin et al., 1999b; Arnoult et al., 2002) . It remains possible that, like cytochrome c, different pools of AIF may exist, which may partially explain this apparent conundrum. Future studies will hopefully provide the answers to these important biological questions.
Are there other regulators that may function in caspaseindependent cell death?
Although many of the studies described in this review establish an important role of AIF in mediating caspaseindependent cell death, several reports have also opened the door to the possible involvement of other caspaseindependent apoptotic effectors. For example, it was shown that certain apoptotic stimuli could still trigger cell death in AIF-deficient ES cells even when caspases are inhibited (Joza et al., 2001) . Furthermore, it was reported that at least in certain death paradigms, caspase-independent chromatin condensation can be triggered in the absence of obvious AIF or EndoG translocation (Arnoult et al., 2003) . Thus, there are likely additional factors that can contribute to the caspase-independent apoptotic process. One such candidate is the AIF homolog AMID (AIF-homologous mitochondrion-associated inducer of death) also known as PRG3 (Ohiro et al., 2002) . As with AIF, AMID/PRG3 has homology with NADH oxidoreductases/flavoproteins, unlike AIF, however, it lacks a recognizable MLS and appears to reside primarily in the cytoplasm or loosely associated with the mitochondrial outer membrane. Interestingly, this protein is induced by p53 (Ohiro et al., 2002) and overexpression studies have demonstrated that it is capable of inducing peripheral chromatin condensation and cell death in the absence of caspase activation . Although AMID represents an intriguing candidate, its physiological importance and relationship to current death pathways remains to be determined. Owing to the many unanswered questions in this field, it is highly likely that additional factors will be discovered and will help to clarify these mechanisms.
Continued study of the mechanisms of apoptosis including caspase-independent death processes are likely to reveal novel therapeutic targets for the treatment of diverse human pathologies including cancer, neurodegenerative diseases and acute injuries such as stroke or myocardial infarction. Presently, caspase-independent death mechanisms represent an area of intensive study with many questions that remain to be answered. Studies with different death paradigms yield distinct mechanisms with respect to: (a) the dependence on caspase; (b) the sequential ordering of mitochondrial events to facilitate apoptosis; and (c) the mechanisms by which these molecules execute cells death. While many of the results that have been recently reported are highly controversial, it appears that the role of mitochondrial factors and how they engage the death machinery vary depending on the apoptotic stimulus and the cell type being examined. Future studies should help to fill in the missing pieces of the apoptotic puzzle.
